Third Universal Definition of Myocardial Infarction Thygesen, Kristian; Alpert, Joseph S; Jaffe, Allan S ...
Journal of the American College of Cardiology,
10/2012, Letnik:
60, Številka:
16
Journal Article, Conference Proceeding, Web Resource
Recenzirano
Odprti dostop
.1595 Abbreviations and acronyms ACCF = American College of Cardiology Foundation ACS = acute coronary syndrome AHA = American Heart Association CAD = coronary artery disease CABG = coronary artery ...bypass grafting CKMB = creatine kinase MB isoform cTn = cardiac troponin CT = computed tomography CV = coefficient of variation ECG = electrocardiogram ESC = European Society of Cardiology FDG = fluorodeoxyglucose h = hour(s) HF = heart failure LBBB = left bundle branch block LV = left ventricle LVH = left ventricular hypertrophy MI = myocardial infarction mlBG = meta-iodo-benzylguanidine min = minute(s) MONICA = Multinational MONItoring of trends and determinants in CArdiovascular disease MPS = myocardial perfusion scintigraphy MRI = magnetic resonance imaging mV = millivolt(s) ng/L = nanogram(s) per liter Non-Q Ml = non-Q wave myocardial infarction NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PET = positron emission tomography pg/mL = pictogram(s) per milliliter Q wave Ml = Q wave myocardial infarction RBBB = right bundle branch block sec = second(s) SPECT = single photon emission computed tomography STEMI = ST elevation myocardial infarction ST-T = ST-segment -T wave URL = upper reference limit WHF = World Heart Federation WHO = World Health Organization Introduction Myocardial infarction (MI) can be recognized by clinical features, including electrocardiographic (ECG) findings, elevated values of biochemical markers (biomarkers) of myocardial necrosis, and by imaging, or may be defined by pathology. Additionally, the management of patients with MI has significantly improved, resulting in less myocardial injury and necrosis, in spite of a similar clinical presentation. ...it appears necessary to distinguish the various conditions which may cause MI, such as 'spontaneous' and 'procedure-related' MI. ...physicians, other healthcare providers and patients require an up-to-date definition of MI.
Third universal definition of myocardial infarction THYGESEN, Kristian; ALPERT, Joseph S; JAFFE, Allan S ...
European heart journal,
10/2012, Letnik:
33, Številka:
20
Journal Article, Conference Proceeding, Web Resource
The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti‐cancer agents ...may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under‐represent older patients and those with significant co‐morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre‐clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross‐disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.
PDF
